(AGL) agilon health - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00857U1079

Stock: Healthcare Platform, Senior Care, Primary Care, Subscription Model

Total Rating 19

Risk 33

Buy Signal -0.47

Medical Care Facilities » Health Care Services
Age: 4.8y

Market Cap: 345m
Avg Trading Vol: 4.96M USD

ATR: 12.13%
Peers RS (IBD): 10.81

EPS (Earnings per Share)

EPS CAGR: -0.18%
EPS Trend: -34.5%

Last SUE: 3.80
Qual. Beats: 1

Revenue

Rev. CAGR: 35.23%
Rev. Trend: 89.2%

Last SUE: 0.21
Qual. Beats: 0

Risk 5d forecast
Volatility	101%
Relative Tail Risk	-10.6%

Reward TTM
Sharpe Ratio	-1.00
Alpha	-87.96

Character TTM
Beta	0.206
Beta Downside	-0.347

Drawdowns 3y
Max DD	98.21%
CAGR/Max DD	-0.71

Description: AGL agilon health January 17, 2026

agilon health, inc. (NYSE:AGL) delivers senior-focused primary care across U.S. communities, operating a subscription-style, per-member-per-month (PMPM) platform that coordinates patients’ full spectrum of healthcare needs. The firm, originally Agilon Health Topco, Inc., rebranded in March 2021 and was founded in 2016 in Westerville, Ohio.

Key performance indicators that analysts watch include the PMPM revenue growth rate (which accelerated to ~18% YoY in Q4 2023) and the net patient-days per physician (a proxy for utilization efficiency). The business is sensitive to macro-level health-care spending trends-particularly Medicare Advantage enrollment growth, which currently rises at ~5% annually and fuels demand for value-based senior care models. A sector-wide driver is the shift toward bundled payments and capitation, which aligns with agilon’s subscription model and can improve margin upside if managed care contracts expand.

For a deeper, data-driven view of agilon’s valuation dynamics, you may find ValueRay’s analytical dashboard worth exploring.

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income: -308.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.06 > 0.02 and ΔFCF/TA 1.51 > 1.0
NWC/Revenue: 1.67% < 20% (prev 7.52%; Δ -5.85% < -1%)
CFO/TA -0.04 > 3% & CFO -68.8m > Net Income -308.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.08 > 1.5 & < 3
Outstanding Shares: last quarter (414.5m) vs 12m ago 0.70% < -2%
Gross Margin: -1.95% > 18% (prev -0.01%; Δ -194.5% > 0.5%)
Asset Turnover: 319.2% > 50% (prev 256.0%; Δ 63.23% > 0%)
Interest Coverage Ratio: -48.42 > 6 (EBITDA TTM -286.6m / Interest Expense TTM 6.50m)

Altman Z'' -5.85

A: 0.06 (Total Current Assets 1.34b - Total Current Liabilities 1.24b) / Total Assets 1.60b
B: -1.12 (Retained Earnings -1.79b / Total Assets 1.60b)
C: -0.17 (EBIT TTM -314.7m / Avg Total Assets 1.84b)
D: -1.38 (Book Value of Equity -1.78b / Total Liabilities 1.29b)
Altman-Z'' Score: -5.85 = D

Beneish M -3.27

DSRI: 0.63 (Receivables 947.2m/1.37b, Revenue 5.89b/5.35b)
GMI: 1.00 (fallback, negative margins)
AQI: 1.25 (AQ_t 0.14 / AQ_t-1 0.11)
SGI: 1.10 (Revenue 5.89b / 5.35b)
TATA: -0.15 (NI -308.3m - CFO -68.8m) / TA 1.60b)
Beneish M-Score: -3.27 (Cap -4..+1) = AA

What is the price of AGL shares?

As of February 09, 2026, the stock is trading at USD 0.65 with a total of 5,531,596 shares traded.
Over the past week, the price has changed by -22.13%, over one month by -20.59%, over three months by -7.06% and over the past year by -80.24%.

Is AGL a buy, sell or hold?

agilon health has received a consensus analysts rating of 3.30. Therefor, it is recommend to hold AGL.

StrongBuy: 4
Buy: 0
Hold: 14
Sell: 2
StrongSell: 0

What are the forecasts/targets for the AGL price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	1	52.3%
Analysts Target Price	1	52.3%
ValueRay Target Price	0.4	-46.2%

AGL Fundamental Data Overview February 03, 2026

P/E Forward = 178.5714
P/S = 0.0586
P/B = 1.1673
Revenue TTM = 5.89b USD
EBIT TTM = -314.7m USD
EBITDA TTM = -286.6m USD
Long Term Debt = 34.9m USD (from longTermDebt, last fiscal year)
Short Term Debt = 35.0m USD (from shortTermDebt, last quarter)
Debt = 37.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -134.6m USD (from netDebt column, last quarter)
Enterprise Value = 210.5m USD (345.0m + Debt 37.1m - CCE 171.7m)
Interest Coverage Ratio = -48.42 (Ebit TTM -314.7m / Interest Expense TTM 6.50m)
EV/FCF = -2.14x (Enterprise Value 210.5m / FCF TTM -98.5m)
FCF Yield = -46.82% (FCF TTM -98.5m / Enterprise Value 210.5m)
FCF Margin = -1.67% (FCF TTM -98.5m / Revenue TTM 5.89b)
Net Margin = -5.24% (Net Income TTM -308.3m / Revenue TTM 5.89b)
Gross Margin = -1.95% ((Revenue TTM 5.89b - Cost of Revenue TTM 6.00b) / Revenue TTM)
Gross Margin QoQ = -5.23% (prev -3.76%)
Tobins Q-Ratio = 0.13 (Enterprise Value 210.5m / Total Assets 1.60b)
Interest Expense / Debt = 4.95% (Interest Expense 1.84m / Debt 37.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -248.6m (EBIT -314.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.08 (Total Current Assets 1.34b / Total Current Liabilities 1.24b)
Debt / Equity = 0.12 (Debt 37.1m / totalStockholderEquity, last quarter 306.1m)
Debt / EBITDA = 0.47 (negative EBITDA) (Net Debt -134.6m / EBITDA -286.6m)
Debt / FCF = 1.37 (negative FCF - burning cash) (Net Debt -134.6m / FCF TTM -98.5m)
Total Stockholder Equity = 421.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -16.72% (Net Income -308.3m / Total Assets 1.60b)
RoE = -73.12% (Net Income TTM -308.3m / Total Stockholder Equity 421.6m)
RoCE = -68.95% (EBIT -314.7m / Capital Employed (Equity 421.6m + L.T.Debt 34.9m))
RoIC = -54.46% (negative operating profit) (NOPAT -248.6m / Invested Capital 456.5m)
WACC = 6.40% (E(345.0m)/V(382.1m) * Re(6.67%) + D(37.1m)/V(382.1m) * Rd(4.95%) * (1-Tc(0.21)))
Discount Rate = 6.67% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.67%
Fair Price DCF = unknown (Cash Flow -98.5m)
EPS Correlation: -34.51 | EPS CAGR: -0.18% | SUE: 3.80 | # QB: 1
Revenue Correlation: 89.23 | Revenue CAGR: 35.23% | SUE: 0.21 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.03 | Chg30d=+0.006 | Revisions Net=+0 | Analysts=7
EPS next Year (2026-12-31): EPS=-0.41 | Chg30d=+0.010 | Revisions Net=+0 | Growth EPS=+47.6% | Growth Revenue=+2.7%

Additional Sources for AGL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle